Toripalimab in advanced biliary tract cancer

Hezel, 2010, Genetics of biliary tract cancers and emerging targeted therapies, J. Clin. Oncol., 28, 3531, 10.1200/JCO.2009.27.4787 Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N. Engl. J. Med., 362, 1273, 10.1056/NEJMoa0908721 Valle, 2014, Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials, Ann. Oncol., 25, 391, 10.1093/annonc/mdt540 Okusaka, 2010, Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan, Br. J. Cancer, 103, 469, 10.1038/sj.bjc.6605779 Morizane, 2019, Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial, Ann. Oncol., 30, 1950, 10.1093/annonc/mdz402 Heymach, 2018, Clinical cancer advances 2018: annual report on progress against cancer from the American society of clinical oncology, J. Clin. Oncol., 36, 1020, 10.1200/JCO.2017.77.0446 Tang, 2019, Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients, J. Hematol. Oncol., 12, 7, 10.1186/s13045-018-0693-2 Zheng, 2021, A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909), Ann. Transl. Med., 9, 73, 10.21037/atm-20-5404 Wang, 2021, Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02), J. Clin. Oncol., 39, 704, 10.1200/JCO.20.02712 Wang, 2019, Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432, Ann. Oncol., 30, 1479, 10.1093/annonc/mdz197 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med., 9, 34, 10.1186/s13073-017-0424-2 Park, 2015, Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review, Cancer Res. Treat, 47, 343, 10.4143/crt.2014.308 Piha-Paul, 2020, Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies, Int. J. Cancer, 147, 2190, 10.1002/ijc.33013 Chen, 2020, Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial, J. Immunother. Cancer, 8, e001240, 10.1136/jitc-2020-001240 Bang, 2019, Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies, J. Clin. Oncol., 37, 4079, 10.1200/JCO.2019.37.15_suppl.4079 Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol., 21, 1353, 10.1016/S1470-2045(20)30445-9 Ueno, 2019, Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study, Lancet Gastroenterol. Hepatol., 4, 611, 10.1016/S2468-1253(19)30086-X Gadgeel, 2018, Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study, Lung Cancer, 125, 273, 10.1016/j.lungcan.2018.08.019 Sasaki, 2013, A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer, Cancer Chemother. Pharmacol., 71, 973, 10.1007/s00280-013-2090-4 Malka, 2014, Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial, Lancet Oncol., 15, 819, 10.1016/S1470-2045(14)70212-8 Lin, 2021, Mutational spectrum and precision oncology for biliary tract carcinoma, Theranostics, 11, 4585, 10.7150/thno.56539 Schoenfeld, 2020, The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer, Clin. Cancer Res., 26, 5701, 10.1158/1078-0432.CCR-20-1825